RVNC NASDAQ
Revance Therapeutics, Inc.
1W: +0.6%
1M: +5.2%
3M: -37.2%
1Y: -28.4%
3Y: -73.0%
5Y: -84.3%
$3.65
Last traded 2025-02-06 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
📊 Key Metrics
TTM$247M
Revenue
+15.3% YoY
$-181M
Net Income
+56.7% YoY
$-195M
Free Cash Flow
+15.3% YoY
70.6%
Gross Margin
-53.9%
Op. Margin
-58.6%
Net Margin
💰 Income Flow
How revenue becomes profit💵 Cash Flow
⚠️ Cash Burn Where cash goes🏦 Balance Sheet
Assets = Liabilities + Equity📈 Financial Health
Profitability
ROE134.8%
ROA-36.5%
ROIC-96.2%
Valuation
P/E-1.0
P/B-2.0
EV/EBITDA-5.6
Leverage
Debt/Equity-2.97
Current Ratio4.12
Interest Cov.-6.8x
Quality Scores
Piotroski F3/9
Altman Z-6.11
Beneish M-1.54